Zoetis Inc. (ZTS) Tax Rate: 20.45%
Is Zoetis Inc.’s tax rate high or low?
Zoetis Inc.'s tax rate of 20.45% is in line with its 5-year average of 19.65%, near the high end of its 5-year range (18.04%–20.52%).
0.29% above its 12-month average of 20.39%.
ZTS Tax Rate Chart
ZTS Average Tax Rate Chart
ZTS Current vs Average Tax Rate Chart
ZTS Tax Rate Metrics
TAX RATE
20.45%
TAX RATE AVG TTM
20.39%
TAX RATE AVG 3Y
20.40%
TAX RATE AVG 5Y
19.65%
TAX RATE AVG 10Y
24.08%
TAX RATE AVG 15Y
27.11%
TAX RATE AVG 20Y
27.38%
CURRENT VS TTM AVG
+0.29%
CURRENT VS 3Y AVG
+0.25%
CURRENT VS 5Y AVG
+4.08%
CURRENT VS 10Y AVG
-15.09%
CURRENT VS 15Y AVG
-24.56%
CURRENT VS 20Y AVG
-25.32%
Zoetis Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Tax Rate FAQ
- What is the tax rate for Zoetis Inc. (ZTS)?
- The tax rate for ZTS stock is 20.45%.
- Is Zoetis Inc.'s tax rate high or low?
- Zoetis Inc.'s tax rate of 20.45% is in line with its 5-year average of 19.65%, near the high end of its 5-year range (18.04%–20.52%).
- What is the TTM average tax rate for Zoetis Inc. (ZTS)?
- The TTM average tax rate for ZTS stock is 20.39%.
- What is the 3Y average tax rate for Zoetis Inc. (ZTS)?
- The 3Y average tax rate for ZTS stock is 20.40%.
- What is the 5Y average tax rate for Zoetis Inc. (ZTS)?
- The 5Y average tax rate for ZTS stock is 19.65%.
- What is the 10Y average tax rate for Zoetis Inc. (ZTS)?
- The 10Y average tax rate for ZTS stock is 24.08%.
- What is the 15Y average tax rate for Zoetis Inc. (ZTS)?
- The 15Y average tax rate for ZTS stock is 27.11%.
- What is the 20Y average tax rate for Zoetis Inc. (ZTS)?
- The 20Y average tax rate for ZTS stock is 27.38%.
Zoetis Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 20.45% |
| 2024-12-31 | 20.33% |
| 2023-12-31 | 20.30% |
| 2022-12-31 | 20.52% |
| 2021-12-31 | 18.25% |
| 2020-12-31 | 18.04% |
| 2019-12-31 | 16.71% |
| 2018-12-31 | 15.74% |
| 2017-12-31 | 43.48% |
| 2016-12-31 | 33.31% |
| 2015-12-31 | 37.80% |
| 2014-12-31 | 28.41% |
| 2013-12-31 | 27.10% |
| 2012-12-31 | 38.59% |
| 2011-12-31 | 37.06% |
| 2010-12-31 | 37.64% |
| 2009-12-31 | 31.76% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck